DOVATO Drug Patent Profile

Which patents cover Dovato, and when can generic versions of Dovato launch?

Dovato is a drug marketed by Viiv Hlthcare and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and one patent family members in forty-nine countries.

The generic ingredient in DOVATO is dolutegravir sodium; lamivudine. There are seventeen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the dolutegravir sodium; lamivudine profile page.

DrugPatentWatch^® Generic Entry Outlook for Dovato

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 8, 2030. This may change due to patent challenges or generic licensing.

There have been twenty-four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for DOVATO

International Patents:	301
US Patents:	3
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DOVATO

Paragraph IV (Patent) Challenges for DOVATO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DOVATO	Tablets	dolutegravir sodium; lamivudine	50 mg/300 mg	211994	1	2019-07-30

US Patents and Regulatory Information for DOVATO

DOVATO is protected by three US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 9,242,986.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	DOVATO	dolutegravir sodium; lamivudine	TABLET;ORAL	211994-001	Apr 8, 2019		RX	Yes	Yes	11,234,985		Y
Viiv Hlthcare	DOVATO	dolutegravir sodium; lamivudine	TABLET;ORAL	211994-001	Apr 8, 2019		RX	Yes	Yes
Viiv Hlthcare	DOVATO	dolutegravir sodium; lamivudine	TABLET;ORAL	211994-001	Apr 8, 2019		RX	Yes	Yes	8,129,385*PED				Y
Viiv Hlthcare	DOVATO	dolutegravir sodium; lamivudine	TABLET;ORAL	211994-001	Apr 8, 2019		RX	Yes	Yes	9,242,986*PED				Y

International Patents for DOVATO

When does loss-of-exclusivity occur for DOVATO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Hong Kong

Japan

Mexico

Russian Federation

Singapore

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering DOVATO around the world.

Country	Patent Number	Title	Estimated Expiration
Poland	3372281
Japan	2016041727	カルバモイルピリドンＨＩＶインテグラーゼ阻害剤及びそれらの中間体の合成 (SYNTHESIS OF CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS AND THEIR INTERMEDIATES)
Eurasian Patent Organization	201290583
Portugal	2932970
Malaysia	207233
Spain	2892304

Supplementary Protection Certificates for DOVATO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2465580	SPC/GB21/030	United Kingdom		PRODUCT NAME: CABOTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING CABOTEGRAVIR SODIUM.; REGISTERED: UK EU/1/20/1481 (NI) 20201221; UK PLGB 35728/0055-57 20201221
2932970	332 50016-2018	Slovakia		PRODUCT NAME: DOLUTEGRAVIR VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM/RILPIVIRIN VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/18/1282/001 - EU/1/18/1282/002 20180518
3494972	122024000031	Germany		PRODUCT NAME: DOLUTEGRAVIR, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, EINSCHLIESSLICH DOLUTEGRAVIR-NATRIUM, MIT LAMIVUDIN; REGISTRATION NO/DATE: EU/1/19/1370 20190701
2932970	300957	Netherlands		PRODUCT NAME: EEN COMBINATIE OMVATTENDE DOLUTEGRAVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN (ZOALS DOLUTEGRAVIR NATRIUM) EN RILPIVIRINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN (ZOALS RILPIVIRINE HYDROCHLORIDE); REGISTRATION NO/DATE: EU/1/18/1282 20180518
1874117	2023C/545	Belgium		PRODUCT NAME: DOULUTEGRAVIR SODIQUE; AUTHORISATION NUMBER AND DATE: EU/1/13/892 20140121
3494972	18/2024	Austria		PRODUCT NAME: DOLUTEGRAVIR ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, EINSCHLIESSLICH DOLUTEGRAVIR-NATRIUM, UND LAMIVUDIN; REGISTRATION NO/DATE: EU/1/19/1370 (MITTEILUNG) 20190703

Investment Scenario and Fundamentals Analysis for Dovato

Last updated: February 19, 2026

What is Dovato?

Dovato (dolutegravir/lamivudine) is an oral fixed-dose combination antiviral drug approved by the US FDA in 2019 for the treatment of HIV-1 infection. It combines two antiretrovirals: dolutegravir, an integrase strand transfer inhibitor (INSTI), and lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI). This combination aims to simplify therapy with a once-daily, two-drug regimen.

Market Overview and Sales Potential

Market Size

• The global HIV/AIDS therapeutics market was valued at approximately USD 25.3 billion in 2022 and is projected to grow at a CAGR of 6% through 2030 [1].

• Dovato's sales reached USD 1.6 billion in 2022, reflecting strong uptake in developed markets [2]. The drug competes primarily with other single-tablet regimens (STRs) such as Genvoya and Biktarvy.

Growth Drivers

• Shift toward dual therapies to reduce long-term toxicity risks (e.g., bone mineral density loss, kidney impairment).

• Increased treatment uptake in countries expanding access, notably in Europe and emerging markets.

• Favorable reimbursement policies and guidelines favoring simplified regimens.

Competitive Landscape

• Key competitors include Biktarvy (Gilead, 2020), Genvoya (Gilead), and Descovy (Gilead). Biktarvy holds the largest market share globally.

• Dovato faces challenges from these established products due to existing patient and clinician familiarity.

Regulatory and Patent Landscape

Patent Status

• Dovato’s core patent protections extend until 2030 in the US, with potential extensions based on formulation and method of use patents [3].

Regulatory Approvals and Indications

• FDA approval for treatment-naïve and virologically suppressed adults.

• EMA approval follows similar indications; ongoing studies aim to support expansion into pediatric use.

Patent Litigation

• Patent litigation between Gilead and generics manufacturers may affect generic entry timelines post-2030.

Clinical and Developmental Fundamentals

Efficacy and Safety

• Clinical trials demonstrate non-inferiority compared to three-drug regimens in viral suppression at 48 weeks.

• Lower risk of drug-drug interactions relative to protease inhibitors.

• Side effects are generally mild; common adverse events include headache, fatigue, and nausea.

Resistance Profile

• Dolutegravir's high barrier to resistance supports a durable regimen.

• Mutations leading to resistance are rare but can occur with non-adherence.

Expansion and Line Extensions

• Research ongoing into Dovato for pre-exposure prophylaxis (PrEP) and pediatric indications.

• Dovato’s once-daily compliance profile enhances adherence potential.

Financial Fundamentals and Investment Considerations

Parameter	Data	Source
2022 global sales	USD 1.6 billion	[2]
Market growth CAGR	6% through 2030	[1]
Patent expiration	2030 in the US	[3]
Peak sales estimates	USD 2.5 billion (by 2025)	Industry reports [4]

R&D and Commercial Expenses

• Gilead invests heavily in R&D for HIV therapies, allocating over USD 500 million annually for HIV pipeline advancement [5].

• Marketing costs focus on resource-rich markets; commercial investments in emerging markets are expanding.

Profitability Outlook

• Gross margins estimated at 80%+ due to high-margin royalties and licensing revenues.

• Royalties from generic manufacturers likely to increase post-2030 if patent protections lapse.

Investment Risks

• Patent expiration risk threatens future exclusivity.

• Market share erosion from competing regimens and emerging therapies.

• Regulatory hurdles in expanding indications.

• Potential for adverse safety findings impacting sales.

Key Takeaways

• Dovato is a leading dual therapy for HIV-1, with strong clinical efficacy and safety profile.

• Market growth driven by the shift toward simplified regimens and expanding access.

• Patent protections extend until 2030, after which generics may impact sales margins.

• Competition from Biktarvy and Genvoya constrains market share growth.

• Investment hinges on continued adoption, regulatory approvals for new indications, and patent lifecycle management.

FAQs

1. What is the main competitive advantage of Dovato?
Its simplified two-drug regimen offers ease of adherence and a favorable safety profile compared to older, three-drug regimens.

2. How will patent expirations affect Dovato’s future revenue?
Post-2030, generics could enter the market, potentially reducing prices and market share unless innovative formulations or indications are developed.

3. What are the primary risks for investors in Dovato?
Patent expiration, increasing competition, regulatory delays in expanding indications, and safety concerns.

4. Are there upcoming clinical trials that could expand Dovato’s indications?
Yes, studies are underway for PrEP and pediatric uses, which could open new revenue streams.

5. How does Dovato compare to other HIV therapies in terms of market share?
It trails Biktarvy, which holds approximately 50% of global market share among STRs, whereas Dovato’s share remains below 20%.

---

References

[1] MarketsandMarkets. (2023). HIV/AIDS Therapeutics Market Forecast.
[2] Gilead Sciences Investor Relations. (2022). Annual Report.
[3] U.S. Patent and Trademark Office. (2022). Patent Status for Dovato.
[4] Industry Reports. (2023). HIV Market Peak Sales Projections.
[5] Gilead Sciences R&D Budget. (2022). Annual Spending Report.